No Data
Dajiahui vicom ltd (301126.SZ) specific shareholder Liangji Investment and its concerted parties completed a shareholding of 1.7391 million shares.
Dajia Vicom Ltd (301126.SZ) announced that as of December 5, 2024, the specific shareholder Ningbo Meishan...
Dajia Weikang (301126.SZ) 81.8702 million shares of restricted shares will be listed and traded on December 9th.
Dajia Vicom Ltd (301126.SZ) announced that the number of shareholders whose restricted shares are released is a total of 5 households, and the restricted shares have been released...
Daga Weikang: Report for the third quarter of 2024
Vicom Ltd (301126.SZ): Its subsidiary, Jiachen Hospital, is actively promoting the application for human assisted reproduction license qualification.
Gelonghui October 11th | Dajia vicom ltd (301126.SZ) stated at an investor relations event that its subsidiary, Jiachen hospital, is actively pursuing the application for human assisted reproduction license qualification. Due to the high barriers of assisted reproduction technology, lengthy licensing application processes, and strict approval standards, there is uncertainty about the prospects of the company's continued assisted reproduction business.
Vicom Ltd (301126.SZ): invested 10 million yuan to establish a wholly-owned subsidiary Vicom Ltd Regenerative Medicine Research Institute.
On September 27, Gelonghui announced that in order to further meet the needs of its global strategy, enhance the company's market competitiveness, the company used its own funds to set up a wholly-owned subsidiary, Hunan Dajiaweikang Regenerative Medical Research Institute Co., Ltd. (hereinafter referred to as "Dajiaweikang Regenerative Medical Research Institute"). Recently, the Dajiaweikang Regenerative Medical Research Institute has completed the industrial and commercial registration and obtained the "Business License" issued by the Changsha County Market Supervision Administration. The establishment of this wholly-owned subsidiary will help further strengthen the company's development in the field of medical services and enhance the company's leading position in this area.
Daga Weikang: 2024 Semi-Annual Report Summary
Investors Still Aren't Entirely Convinced By Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Revenues Despite 28% Price Jump
No Data
